Wake Forest researchers and clinicians are using patient-specific tumor ‘organoid’ models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer.
Daniel Catenacci, MD, a physician-scientist and associate professor of medicine at UChicago Medicine, has received the National Cancer Institute (NCI) 2021 Cancer Clinical Investigator Team Leadership Award (CCITLA).
UCLA Health will receive a $4.8 million grant from The National Institutes of Health to develop methods that will improve genetic risk estimates – polygenic risk scores – for specific diseases in people from diverse populations and mixed ancestries.
Digital twins enable customized medical therapies. Empa researchers have now modeled several hundred such avatars based on real people and treated them experimentally. For the first time, the digital twins received feedback from real patients.
To improve the development of new saliva-based diagnostic tests and personalized medicine, the National Institute of Dental and Craniofacial Research (NIDCR) has supported the development of the Human Salivary Proteome Wiki, the first public platform that catalogs and curates data on each of the thousands of proteins within our saliva.
To lower hospital readmission rates for patients with chronic obstructive pulmonary disease (COPD), University at Buffalo pharmacy researcher David Jacobs has received a $962,000 award from the National Heart, Lung, and Blood Institute to develop a real-time readmission risk prediction algorithm.
In a recent perspective article, pathologists outline how the immunome — all of the genes collectively expressed by an individual’s immune cells — holds the potential to provide researchers and physicians with unprecedented insight into an individual’s health. Collecting that information from large numbers of patients could one day facilitate diagnostics via a near-universal blood test and pave the way to targeted therapies for a wide variety of conditions.
New study identifies a novel approach for tailored treatment that could be more effective for patients with the chronic disease
As yet there is no prescription drug to cure mild cognitive impairment (MCI), often a harbinger of Alzheimer’s disease. Medical research journals reveal curcumin can sometimes bolster cognition. It merits a try.
UC San Diego researchers use experimental artificial intelligence system called DrugCell to predict the best approach to treating cancer.
Brendan G. Carr, MD, MA, MS, and Judy H. Cho, MD, of the Icahn School of Medicine at Mount Sinai, have been elected to the National Academy of Medicine (NAM).
A multidisciplinary team from Columbia Engineering, Columbia’s College of Dental Medicine and Department of Medicine, Louisiana State University, LaCell LLC, and Obatala Sciences has now bioengineered living cartilage-bone temporomandibular joint grafts, precisely matched to the recipient, both biologically and anatomically. Their new study, published today in Science Translational Medicine, builds upon a long series of their previous work on bioengineering functional cartilage and bone for regenerative medicine and tissue models of disease.
Post-translational modification analysis may broadly identify new biomarkers of cancer drivers for a much more precise prediction of patient responses to treatments. A recent study demonstrates this diagnostic alternative for neuroendocrine neoplasms driven by a protein kinase called Cdk5.
Coriell Life Sciences is rolling out a new tool in the fight against COVID-19: personalized COVID-19 Risk Scores designed to enable safer re-opening and return to work plans (especially given the recent release of the CDC guidelines for re-opening).
Is personalized medicine cost-effective? Researchers have answered that question for one medical treatment, genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI. Their study uses pharmacogenomics and economic analysis of real-world clinical data.
The promise of personalized medicine has not fully materialized, say two McMaster researchers, because the full sophistication of the genetic blueprint has a more complex and far-reaching influence on human health than scientists had first realized.
Just released is the April edition of SLAS Technology featuring cover article, “CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence,” by Agata Blasiak, Ph.D., Jeffrey Khong, Ph.D., and Theodore Kee, Ph.D., (University of Singapore and The N.1 Institute for Health).
Obesity is among the most common complex diseases in the United States and has been a stubborn public health challenge for decades. Its causes are wide ranging, but genetic heritability is increasingly understood to be an influential factor in determining a person’s risk for the disease. Coriell researchers have found a new genetic indicator of obesity risk and bolstered the understood importance of one gene’s role in obesity risk.
Rutgers biomedical engineers have developed a “bio-ink” for 3D printed materials that could serve as scaffolds for growing human tissues to repair or replace damaged ones in the body. Their study was published in the journal Biointerphases.
Using machine learning to analyze data on nearly 600,000 pregnancies, researchers devised an algorithm that identified nine parameters – out of more than 2,000 analyzed – that can predict which women are at risk of gestational diabetes. The parameters can identify risk early in – even before – pregnancy, enabling early intervention.
Personalised cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to University of South Australia researcher Dr Stephanie Reuter Lange to explore how computer-based modelling can optimise cancer treatment and remove the need for expensive clinical trials.
New findings show that individual variations in the brain’s structural connectome (map of neural connections) define a specific structural fingerprint with a direct impact on the functional organization of individual brains.
Findings may inform genetic screening test for patients at risk and medically under-served
NCCN Guidelines for Genetic/Familial Risk Assessment: Breast, Ovarian, and Pancreatic updated with new and expanded sections on risk assessment and management related to three major cancer types.
The lack of understanding of health providers and patients is a major barrier to the integration of genomics into personalized medicine. This innovative certificate program will provide health professionals and scientists with the requisite skills they need to interpret and incorporate this new knowledge into a patient care model that emphasizes individually tailored prevention, diagnosis and treatment.
The Ohio State University Wexner Medical Center’s Heart and Vascular Center has named Dr. Dan Roden, senior vice president for Personalized Medicine at Vanderbilt University Medical Center, as recipient of the 2019 Jay and Jeanie Schottenstein Prize in Cardiovascular Sciences.
Wearable, smart technologies are transforming the ability to monitor and improve health, but a decidedly low-tech commodity — the humble toilet — may have potential to outperform them all.
New Precision Immunotherapy Therapy clinic at Moores Cancer Center at UC San Diego Health matches patients using genetic profiling to personalized cancer treatment plans.
Breast cancer specialist Laura Esserman, MD, MBA, is being honored for excellence in the field of cancer research with an award from the University of Chicago Medicine Comprehensive Cancer Center.
In the October Special Issue of SLAS Technology, Guest Editors Soojung Claire Hur, Ph.D., and Deok-Ho Kim, Ph.D., (Johns Hopkins University; Baltimore, MD, USA) introduce a collection of articles and reviews focused on the advancement in technologies that are playing a major role in shifting healthcare closer to more predictive, preventative and personalized medicine.
The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.